Navigation Links
Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Date:3/24/2008

Potential NDA Submission in 2009

SEATTLE, March 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) announced today that enrollment is complete in the phase III EXTEND (PIX301) clinical trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL). An analysis of the data is expected in the second half of 2008. Based on prior discussions with the U.S. Food and Drug Administration (FDA) the data could provide a registration path for pixantrone if final study results are adequate for submitting a New Drug Application (NDA) with the FDA in early 2009 with a potential approval in 2009. A total of 140 patients were enrolled in the study, 97 patients are currently evaluable according to Histological Intent to Treat, or HITT, criteria and will be included in the final analysis of the study.

"PIX301 examines the effectiveness of pixantrone in patients with relapsed and refractory diffuse large B cell lymphoma, a population where current therapies seldom induce complete remissions," said Jack W. Singer, Chief Medical Officer at CTI. "Based on a blinded current independent assessment of events in the trial we believe we have an adequate sample size of eligible patients to meet the primary objective of the trial."

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. Patients were randomized to receive either pixantrone or another single-agent drug currently used
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
2. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
3. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
4. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
8. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
9. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
10. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
11. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... JOSE, Calif. , Oct. 1, 2014  SI-BONE, Inc., ... iFuse Implant System, ® a minimally invasive surgical (MIS) ... (SI) joint, today announced the expansion of its European operations ... Mr. Eric Schaber as General Manager, Germany.  Mr. ... currently vice president of Europe , ...
(Date:10/1/2014)... Switzerland , October 1, 2014 ... and Next Generation Sequencing (NGS) data analysis, today launches ... full cystic fibrosis analysis in a single NGS experiment. ... of all types of variants in a single NGS ... now, it has not been possible to simultaneously analyse ...
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... MacMillan , Hologic,s President and Chief Executive Officer, will ... on October 1, the first day of Breast Cancer ... the Company,s campaign focused on the important benefits of ... by the FDA as clinically superior to traditional mammography. ...
Breaking Medicine Technology:SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3
... Water Street Healthcare Partners , a strategic private ... announced today that it has completed a sale and ... CareCentrix is the nation,s leading provider of ... industry.  Water Street sold its majority interest in CareCentrix ...
... COPENHAGEN, Denmark and LAGUNA NIGUEL, Calif., Sept. 20, ... today announced that the two companies have entered ... manufacture of bulk IB1001, Inspiration,s intravenous recombinant factor ... of bleeding in individuals with hemophilia B. Under ...
Cached Medicine Technology:Water Street Healthcare Partners Completes Sale and Recapitalization of CareCentrix 2Water Street Healthcare Partners Completes Sale and Recapitalization of CareCentrix 3CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 2CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 3
(Date:10/1/2014)... Engineering and Physical Sciences Research Council (EPSRC) will ... industrial control systems which run, for example, manufacturing ... rail network. , The research will help ... infiltrating the systems behind our critical national infrastructure. ... Control Systems (RITICS), based at Imperial College London, ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog ... prices for smokers. , Smoking will always have a ... is the best method to find affordable coverage. Insurance ... need coverage. , Whole life insurance premiums will ... Since the coverage is permanent, the initial rates ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... Maine (PRWEB) October 01, 2014 Between ... disorders in the U.S., according to figures from the ... Related Diseases Association (AARDA), and many of them have ... chance of having undiagnosed celiac disease. Gluten Free ... raise awareness of undiagnosed celiac disease by publishing a ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... The U.S. Food and Drug Administration (FDA) has decided ... (R) (infliximab) to be used in the treatment of ... today. Crohn's disease affects the gastrointestinal tract and causes ... now there is no drug to treat children who ...
... Illinois at Chicago in collaboration with their colleagues from ... enzyme in the virus that causes SARS//, severe acute ... in the March 27 issue of the Proceedings of ... form a new drug target for drug makers. ...
... the cause of four men whose lives took a turn ... German company// TeGenero and medical research company Parexel, has received ... handling the case, has felt ignored after receiving no response ... conducted at Northwick Park Hospital in Harrow, north-west London, last ...
... It is already known to us that some popular spices ... Liu, an assistant professor of obstetrics// and gynecology at the ... powder dissolved in solution by putting it on ovarian cancer ... that ginger can kill ovarian cancer cells. But the study ...
... Harris Interactive? for the Vagisil Women's Health CenterSM conducted a ... of today's American women are taking active roles in their ... thirds of women aged 18 and older (63 percent) report ... go to a gynecologist, 61 percent say they "always" go ...
... the risk of coronary heart attack and could in general be ... study of 4,400 men and women aged 65 and over by ... a link between the amount of alcohol drunk and the likelihood ... ,People who drink 14 or more glasses of wine or ...
Cached Medicine News:Health News:FDA Accords Priority Review For Pediatric Crohn's Disease Drug 2Health News:Spices Could Be Employed To Treat Certain Cancers 2Health News:Women aware of “feminine health” : their attitud 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: